Neumeier Poma Investment Counsel LLC Has $17.77 Million Holdings in Prestige Consumer Healthcare Inc. $PBH

Neumeier Poma Investment Counsel LLC grew its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 119.5% in the 2nd quarter, HoldingsChannel reports. The fund owned 222,495 shares of the company’s stock after buying an additional 121,145 shares during the period. Prestige Consumer Healthcare makes up about 1.7% of Neumeier Poma Investment Counsel LLC’s holdings, making the stock its 29th biggest holding. Neumeier Poma Investment Counsel LLC’s holdings in Prestige Consumer Healthcare were worth $17,766,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Cerity Partners LLC grew its position in Prestige Consumer Healthcare by 3.7% in the 1st quarter. Cerity Partners LLC now owns 3,666 shares of the company’s stock valued at $315,000 after purchasing an additional 132 shares during the period. UMB Bank n.a. lifted its stake in shares of Prestige Consumer Healthcare by 81.8% in the second quarter. UMB Bank n.a. now owns 320 shares of the company’s stock valued at $26,000 after buying an additional 144 shares in the last quarter. Bank of Montreal Can grew its holdings in shares of Prestige Consumer Healthcare by 2.0% during the second quarter. Bank of Montreal Can now owns 9,351 shares of the company’s stock valued at $747,000 after buying an additional 182 shares during the last quarter. Resona Asset Management Co. Ltd. increased its position in shares of Prestige Consumer Healthcare by 2.3% during the first quarter. Resona Asset Management Co. Ltd. now owns 9,105 shares of the company’s stock worth $783,000 after acquiring an additional 203 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its holdings in shares of Prestige Consumer Healthcare by 312.5% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company’s stock worth $26,000 after acquiring an additional 250 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors.

Prestige Consumer Healthcare Stock Performance

Shares of PBH opened at $59.23 on Wednesday. The stock has a 50 day moving average of $62.07 and a 200 day moving average of $72.07. The company has a market capitalization of $2.85 billion, a price-to-earnings ratio of 13.90, a PEG ratio of 1.93 and a beta of 0.41. Prestige Consumer Healthcare Inc. has a 12 month low of $58.50 and a 12 month high of $90.04. The company has a current ratio of 4.38, a quick ratio of 2.99 and a debt-to-equity ratio of 0.55.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, November 6th. The company reported $1.07 earnings per share for the quarter, topping the consensus estimate of $0.97 by $0.10. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The business had revenue of $274.11 million for the quarter, compared to analysts’ expectations of $257.14 million. During the same quarter in the previous year, the firm earned $1.09 earnings per share. The business’s revenue was down 3.4% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. As a group, sell-side analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Oppenheimer cut their price target on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a research note on Tuesday, October 21st. Wall Street Zen cut Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, November 10th. Canaccord Genuity Group dropped their price objective on Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $85.33.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.